Vascepa is a prescription medication that contains the active ingredient icosapent ethyl, which is used to treat high levels of triglycerides in the blood. The drug works by reducing the production of triglycerides in the liver and increasing their clearance from the bloodstream [1].

The drug patent information for Vascepa shows that it is available in the form of capsules containing 1 gram of icosapent ethyl [2]. The FDA label for Vascepa also confirms that it is available in the form of soft gelatin capsules [3].

A clinical trial conducted to evaluate the effect of Vascepa on the pharmacokinetics of a co-administered drug (warfarin) showed that Vascepa did not affect the absorption, distribution, metabolism, or excretion of warfarin [4].

In conclusion, there is no evidence to suggest that Vascepa can improve drug absorption. While Vascepa is available in the form of soft gelatin capsules, a clinical trial showed that it did not affect the pharmacokinetics of a co-administered drug [1][2][3][4].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf
[3] https://clinicaltrials.gov/ct2/show/NCT02926027
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636097/